FY2025 EPS Estimates for Shattuck Labs, Inc. Cut by Analyst (NASDAQ:STTK)

Shattuck Labs, Inc. (NASDAQ:STTK) – Investment analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for Shattuck Labs in a report issued on Wednesday, April 10th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.00) for the year, down from their prior forecast of ($1.95). HC Wainwright has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.85) per share.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 target price on shares of Shattuck Labs in a research note on Tuesday, April 9th.

Shattuck Labs Trading Down 2.8 %

NASDAQ:STTK opened at $9.34 on Monday. Shattuck Labs has a 1 year low of $1.33 and a 1 year high of $11.11. The firm has a 50 day moving average of $9.15 and a 200-day moving average of $6.12. The stock has a market capitalization of $443.37 million, a P/E ratio of -4.56 and a beta of 2.11.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.10. The company had revenue of $0.71 million for the quarter, compared to the consensus estimate of $0.50 million. Shattuck Labs had a negative return on equity of 63.08% and a negative net margin of 5,268.44%.

Institutional Trading of Shattuck Labs

Institutional investors and hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC acquired a new position in shares of Shattuck Labs in the 1st quarter valued at $30,000. UBS Group AG grew its holdings in shares of Shattuck Labs by 62.3% in the 1st quarter. UBS Group AG now owns 10,978 shares of the company’s stock valued at $32,000 after buying an additional 4,214 shares during the period. Balyasny Asset Management LLC acquired a new position in shares of Shattuck Labs in the 3rd quarter valued at $35,000. Acadian Asset Management LLC acquired a new position in shares of Shattuck Labs in the 1st quarter valued at $37,000. Finally, Jane Street Group LLC acquired a new position in shares of Shattuck Labs in the 1st quarter valued at $58,000. Institutional investors own 58.74% of the company’s stock.

Insider Buying and Selling

In related news, insider Stephen Stout sold 16,004 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $10.53, for a total value of $168,522.12. Following the completion of the transaction, the insider now owns 74,437 shares in the company, valued at approximately $783,821.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 9.89% of the stock is currently owned by corporate insiders.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.